Triptolide markedly attenuates albuminuria and podocyte injury in an animal model of diabetic nephropathy

Ma,Ruixia; Liu,Liqiu; Liu,Xuemei; Wang,Yan; Jiang,Wei; Xu,Luo

doi:10.3892/etm.2013.1226

Triptolide markedly attenuates albuminuria and podocyte injury in an animal model of diabetic nephropathy

Authors:
- Ruixia Ma
- Liqiu Liu
- Xuemei Liu
- Yan Wang
- Wei Jiang
- Luo Xu
View Affiliations

Affiliations: Department of Nephrology, Affiliated Hospital of Qingdao University Medical College, Qingdao, Shandong 266021, P.R. China, Department of Pathophysiology, Qingdao University Medical College, Qingdao, Shandong 266021, P.R. China
Published online on: July 17, 2013 https://doi.org/10.3892/etm.2013.1226
Pages: 649-656

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triptolide is a major active component of Tripterygium wilfordii Hook F, which exerts marked immunosuppressive, anti‑inflammatory and podocyte‑protective effects. In this study, the ability of triptolide to inhibit inflammation and attenuate podocyte injury was examined in a rat model of diabetic nephropathy (DN). Type II diabetic rats with DN were treated with triptolide at a dose of 100 µg.kg‑1.day‑1. Following 8 weeks of triptolide treatment, the urine albumin level, kidney weight/body weight and the number of cells positive for ED‑1 (a marker for rat mononuclear macrophages) in the kidney were assessed. The effects of triptolide on podocyte injury and chronic inflammation were analyzed using quantitative polymerase chain reaction (qPCR), western blotting and immunohistochemistry. Following triptolide treatment, the albuminuria in the type II diabetic rats was significantly reduced. Furthermore, the glomerular hypertrophy and foot process effacement were improved, and there was a recovery of the slit diaphragm associated with nephrin and podocin expression. The inflammation in the kidneys was also attenuated. Furthermore, triptolide significantly reduced the expression of transforming growth factor‑β1 and osteopontin, and the infiltration of ED‑1‑positive cells into the kidney. The results demonstrated that triptolide markedly attenuated albuminuria and podocyte injury in the rat model of DN, which may have been correlated with the inhibition of inflammation and macrophage infiltration in the kidneys.

View Figures

View References

1	Murphy M, Crean J, Brazil DP, Sadlier D, Martin F and Godson C: Regulation and consequences of differential gene expression in diabetic kidney disease. Biochem Soc Trans. 36:941–945. 2008. View Article : Google Scholar : PubMed/NCBI
2	Stitt-Cavanagh E, MacLeod L and Kennedy C: The podocyte in diabetic kidney disease. ScientificWorldJournal. 14:1127–1139. 2009. View Article : Google Scholar
3	Wolf G, Chen S and Ziyadeh FN: From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes. 54:1626–1634. 2005. View Article : Google Scholar : PubMed/NCBI
4	Mitu GM, Wang S and Hirschberg R: BMP7 is a podocyte survival factor and rescues podocytes from diabetic injury. Am J Physiol Renal Physiol. 293:F1641–F1648. 2007. View Article : Google Scholar : PubMed/NCBI
5	Patrakka J and Tryggvason K: Nephrin - a unique structural and signaling protein of the kidney filter. Trends Mol Med. 13:396–403. 2007. View Article : Google Scholar : PubMed/NCBI
6	Marshall SM: The podocyte: a potential therapeutic target in diabetic nephropathy? Curr Pharm Des. 13:2713–2720. 2007. View Article : Google Scholar : PubMed/NCBI
7	Wolf G and Ziyadeh FN: Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol. 106:26–31. 2007. View Article : Google Scholar
8	Kikuchi Y, Imakiire T, Yamada M, et al: Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats. Nephrol Dial Transplant. 20:1573–1581. 2005. View Article : Google Scholar : PubMed/NCBI
9	Williams MD and Nadler JL: Inflammatory mechanisms of diabetic complications. Curr Diab Rep. 7:242–248. 2007. View Article : Google Scholar
10	Ziyadeh FN and Wolf G: Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev. 4:39–45. 2008. View Article : Google Scholar : PubMed/NCBI
11	Wei X, Gong J, Zhu J, et al: Therapeutic effects of triptolide on interleukin-10 gene-deficient mice with colitis. Int Immunopharmacol. 8:1808–1812. 2008. View Article : Google Scholar : PubMed/NCBI
12	Chan SC, Shum DK, Tipoe GL, Mak JC, Leung ET and Ip MS: Upregulation of ICAM-1 expression in bronchial epithelial cells by airway secretions in bronchiectasis. Respir Med. 102:287–298. 2008. View Article : Google Scholar : PubMed/NCBI
13	Lin N, Liu C, Xiao C, et al: Triptolide, a diterpenoid triepoxide, suppresses inflammation and cartilage destruction in collagen-induced arthritis mice. Biochem Pharmacol. 73:136–146. 2007. View Article : Google Scholar : PubMed/NCBI
14	Song HX, Gong J and Chen W: Effect of triptolide on urinary monocyte chemottractant protein-1 in patients with diabetic nephropathy. Zhongguo Zhong Xi Yi Jie He Za Zhi. 25:416–418. 2005.(In Chinese).
15	Ma RX, Liu LQ, Xu Y and Jiang W: Protective effect of triptolide on renal tissues in type 2 diabetic rats. Chinese Journal of Hypertension. 16:1120–1124. 2008.(In Chinese).
16	Yamamoto Y, Maeshima Y, Kitayama H, et al: Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes. 53:1831–1840. 2004. View Article : Google Scholar : PubMed/NCBI
17	Danda RS, Habiba NM, Rincon-Choles H, et al: Kidney involvement in a nongenetic rat model of type 2 diabetes. Kidney Int. 68:2562–2571. 2005. View Article : Google Scholar : PubMed/NCBI
18	Guo XH, Liu ZH, Li H, et al: A novel rat model of type 2 diabetes mellitus. Chinese Journal of Nephrology Dialysis & Transplantation. 9:351–355. 2000.(In Chinese).
19	Jefferson JA, Shankland SJ and Pichler RH: Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int. 74:22–36. 2008. View Article : Google Scholar : PubMed/NCBI
20	Hauser PV, Collino F, Bussolati B and Camussi G: Nephrin and endothelial injury. Curr Opin Nephrol Hypertens. 18:3–8. 2009. View Article : Google Scholar : PubMed/NCBI
21	Baelde HJ, Eikmans M, Lappin DW, Doran PP, Hohenadel D, Brinkkoetter PT, van der Woude FJ, et al: Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int. 71:637–645. 2007. View Article : Google Scholar : PubMed/NCBI
22	Mathieson PW: Update on the podocyte. Curr Opin Nephrol Hypertens. 18:206–211. 2009. View Article : Google Scholar
23	Wittmann S, Daniel C, Stief A, Vogelbacher R, Amann K and Hugo C: Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat. Transplantation. 87:1290–1299. 2009. View Article : Google Scholar : PubMed/NCBI
24	Eto N, Wada T, Inagi R, et al: Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int. 72:455–463. 2007. View Article : Google Scholar : PubMed/NCBI
25	Zhang Y, Chen B, Hou XH, et al: Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats. Chin Med J (Engl). 120:988–995. 2007.PubMed/NCBI
26	Chen ZH, Qin WS, Zeng CH, et al: Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro. Kidney Int. 77:974–988. 2010. View Article : Google Scholar : PubMed/NCBI
27	Zheng CX, Chen ZH, Zeng CH, Qin WS, Li LS and Liu ZH: Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro. Kidney Int. 74:596–612. 2008. View Article : Google Scholar : PubMed/NCBI
28	Gao Q, Shen W, Qin W, et al: Treatment of db/db diabetic mice with triptolide: a novel therapy for diabetic nephropathy. Nephrol Dial Transplant. 25:3539–3547. 2010. View Article : Google Scholar : PubMed/NCBI
29	Tarabra E, Giunti S, Barutta F, et al: Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes. 58:2109–2118. 2009. View Article : Google Scholar
30	Lee EY, Chung CH, Khoury CC, et al: The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability. Am J Physiol Renal Physiol. 297:F85–F94. 2009. View Article : Google Scholar : PubMed/NCBI
31	Tossidou I, Starker G, Kruger J, et al: PKC-alpha modulates TGF-beta signaling and impairs podocyte survival. Cell Physiol Biochem. 24:627–634. 2009. View Article : Google Scholar : PubMed/NCBI
32	Takano Y, Yamauchi K, Hayakawa K, et al: Transcriptional suppression of nephrin in podocytes by macrophages: roles of inflammatory cytokines and involvement of the PI3K/Akt pathway. FEBS Lett. 581:421–426. 2007. View Article : Google Scholar : PubMed/NCBI
33	Kim YH, Lee SH, Lee, Choi SW, Park JW and Kwon TK: Triptolide inhibits murine inducible nitric oxide synthase expression by down-regulating lipopolysaccharide-induced activity of nuclear factor-kappa B and c-Jun NH₂-terminal kinase. Eur J Pharmacol. 494:1–9. 2004. View Article : Google Scholar
34	Zhou Y, Ling EA and Dheen ST: Dexamethasone suppresses monocyte chemoattractant protein-1 production via mitogen activated protein kinase phosphatase-1 dependent inhibition of Jun N-terminal kinase and p38 mitogen-activated protein kinase in activated rat microglia. J Neurochem. 102:667–678. 2007. View Article : Google Scholar